Intersect ENT won FDA approval for the smaller version of its Propel sinus implant, the Propel mini. Following endoscopic sinus surgery, the Propel is implanted and its springiness helps to keep the sinus open. To control local inflammation, it slowly releases mometasone furoate steroid that’s embedded into the implant’s body. The Propel itself eventually gets absorbed by the body so a follow-up to remove it is not necessary.
The Propel mini is essentially the same device, containing the same dose of mometasone furoate, but is designed for less extensive surgeries and for folks with smaller relevant anatomy.